Trial Profile
A study comparing the efficacy and characteristics of HIV infected patients who are on Emtricitabine/rilpivirine/tenofovir-disoproxil-fumarate combination therapy as first line regimen or in switch strategy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Mar 2016
Price :
$35
*
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2016 New trial record